Brief: Health Canada Authorizes Emergency Use Of Leronlimab For Treatment Of First Triple-Negative Breast Cancer Patient In Canada
16/11/2021 21:16
Nov 16 (Reuters) - Cytodyn Inc CYDY.PK :
* HEALTH CANADA AUTHORIZES EMERGENCY USE OF LERONLIMAB FOR
TREATMENT OF FIRST TRIPLE-NEGATIVE BREAST CANCER PATIENT IN
CANADA
Source text for Eikon: ID:nBw3bHbBga
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer